Jay & Jeanie Schottenstein Prize | Ohio State Medical Center

The Jay and Jeanie Schottenstein Prize in Cardiovascular Sciences provides national and international recognition and support to those at the forefront of cardiovascular sciences. The recipient will be a leader in cardiovascular sciences, a physician or biomedical scientist who has made extraordinary and sustained leadership contributions to improving health care.

Established by a $2 million endowment from humanitarian philanthropists Jay and Jeanie Schottenstein, the prize is chartered to The Ohio State University Wexner Medical Center’s Heart and Vascular Center, and will be awarded biennially.

The Schottenstein Laureate will also receive an honorarium of $100,000 (US).

Eligibility and award details

This prestigious prize provides national and international recognition to a physician or biomedical scientist who has made extraordinary and sustained leadership contributions to improving healthcare; or who has successfully pursued innovative biomedical research with demonstrated translational beneﬁts to patient care. Those honored will be practitioners and/or scientists whose accomplishments and contributions have taken place over a career of dedicated and focused scientiﬁc discovery. The prize is awarded biennially.

All nominations must be received by April 16, 2025. Please note that by accepting the award, the 2025 Schottenstein Prize Laureate will agree to attend a two-day series of scheduled events including presentations and research recognition ceremony(s) at The Ohio State University (in the event of pandemic-related travel restrictions an alternate format or timeline for visit will be arranged).

2025 nomination process

The nomination process is a two-step process. No nomination will be considered unless both steps have been completed. Deadline for all entries is April 23, 2025.

Complete and submit the 2025 nomination form about the nominee and the nominator.
These items must be sent for the nominee to be considered:
*Note that we may contact the nominator for additional reference materials after the nominations have been reviewed.
- A letter from the nominator describing the primary reasons by which the nominee merits consideration for the prize. Relevant criteria might include scientiﬁc innovation, creativity, leadership, education, dedication and importance of the nominee’s work to the ﬁeld of cardiovascular research. Consideration will also be given to the nominee’s role as mentor of young researchers and/or clinicians.
- Nominee’s curriculum vitae

Send all required documentation via email to Lily.Dixon@osumc.edu. In the subject line enter the name of the nominee along with Schottenstein Prize Nomination Information. For example: Subject: John Smith – Schottenstein Prize Nomination Information.

Hard copies may be mailed instead of emailing. To request a PDF version of the nomination form to be emailed to you please contact Lily.Dixon@osumc.edu.

Items must be postmarked by April 23, 2025 to be considered. Late entries will not be accepted.

Please mail any hard copy entries to the following:

Lily Dixon
Heart and Vascular Center
ATTN: Schottenstein Prize Nomination Committee
The Ohio State University Heart and Vascular Center
452 W. 10th Ave.
Columbus, OH 43210

Past Winners of the Schottenstein Prize

Christine Seidman, MD

2011 Prize Laureate

Christine Seidman, MD, is professor in the departments of Medicine and Genetics at Harvard Medical School and Brigham and Women’s Hospital, where she is also the Thomas W. Smith Professor of Medicine.

Pascal Goldschmidt, MD

2009 Prize Laureate

Pascal Goldschmidt, MD, was the inaugural recipient of the Schottenstein Prize. He’ is a cardiologist and cardiovascular researcher, and former dean of the University of Miami Leonard M. Miller School of Medicine. Until January 2016, he also served as chief executive officer of the University of Miami Health System. He is currently president and CEO of American Healthcare System, European Care Global and Alzady International.

Richard Kitsis, MD

2023 Laureate

Richard Kitsis, MD, is a professor of Medicine and Cell Biology, where he holds the Dr. Gerald and Myra Dorros Chair in Cardiovascular Disease. He also serves as the Director of the Wilf Family Cardiovascular Research Institute at the Albert Einstein College of Medicine and Montefiore Medicine in New York City. His laboratory has delineated fundamental mechanisms of cell death and roles of cell death in heart disease. This work has established that regulated forms of cell death are primarily responsible for heart damage during myocardial infarction and delineated novel molecular mechanisms that have provided the basis for drug development.

Mark Anderson, MD, PhD

2021 Laureate

A renowned scholar, physician and caregiver, Anderson's research, commitment to education and medical leadership have earned international recognition. He is a leading expert on the mechanisms of cardiac arrhythmias and heart failure, conducting research focused on the role of the calmodulin-dependent protein kinase II (CaMKII) in heart failure and cardiac arrhythmias, which are a common cause of sudden cardiac death. In a seminal 2008 study, his team found that CaMKII could be activated by the oxidization of the amino acid methionine, allowing the protein to sustain its activity even without the presence of calcium or calmodulin. This mechanism, and its activation by angiotensin II-induced oxidation, can lead to cell death in cardiomyocytes, while later work showed that oxidized CaMKII contributes to atrial fibrillation, heart failure and asthma. His work, most recently funded by an Outstanding Investigator Award from the National Heart, Lung, and Blood Institute, has continued to explore the potential for targeting oxidized CaMKII in treating atrial fibrillation and heart failure without inadvertently inhibiting the molecule's critical role in the brain.

Dan Roden, MD

2019 Laureate

Dan Roden, MD, is at Vanderbilt University School of Medicine, where he serves as a professor of Medicine, Pharmacology and Biomedical Informatics and senior vice president for Personalized Medicine at Vanderbilt University Medical Center. After serving as chief of the Division of Clinical Pharmacology for 12 years, he was tasked in 2006 with leading Vanderbilt’s efforts in personalized medicine. He’s been principal investigator for the Vanderbilt sites of the Pharmacogenomics Research Network since 2001 and of the Electronic Medical Records and Genomics Network since 2007.

Helen Hobbs, MD

2017 Prize Laureate

Helen Hobbs, MD, is a professor of Internal Medicine and Molecular Genetics at UT Southwestern Medical Center. She is co-director of the Hobbs-Cohen Lab in the Eugene McDermott Center for Human Growth and Development. Since 2002, she has been a Howard Hughes Investigator. Dr. Hobbs was elected to the Institute of Medicine in 2004 and the National Academy of Sciences in 2007, and was awarded the Breakthrough Prize in Life Sciences in 2015 and the Passano Award (with Jonathan Cohen) in 2016. She is the Philip O'Bryan Montgomery Jr., M.D., Distinguished Chair in Developmental Biology and the Eugene McDermott Distinguished Chair for the Study of Human Growth and Development.

Roberto Bolli, MD, FAHA

2015 Prize Laureate

Roberto Bolli,MD, is professor of Medicine, Physiology and Biophysics; Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology; executive vice chair of the Department of Medicine; director of the Institute of Molecular Cardiology; and Distinguished University Scholar at the University of Louisville School of Medicine.

Garret FitzGerald, MD

2013 Prize Laureate

Garret FitzGerald, MD, is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he chairs the Department of Pharmacology and directs the Institute for Translational Medicine and Therapeutics.